The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia

1990 ◽  
Vol 76 (1) ◽  
pp. 33-38 ◽  
Author(s):  
G. J. Morgan ◽  
A. Hernandez ◽  
L. C. Chan ◽  
T. Hughes ◽  
P. Martiat ◽  
...  
2021 ◽  
Vol 12 (8) ◽  
Author(s):  
Dawei Chen ◽  
Zhenguo Zhao ◽  
Lu Chen ◽  
Qinghua Li ◽  
Jixue Zou ◽  
...  

AbstractEmerging evidence has demonstrated that alternative splicing has a vital role in regulating protein function, but how alternative splicing factors can be regulated remains unclear. We showed that the PPM1G, a protein phosphatase, regulated the phosphorylation of SRSF3 in hepatocellular carcinoma (HCC) and contributed to the proliferation, invasion, and metastasis of HCC. PPM1G was highly expressed in HCC tissues compared to adjacent normal tissues, and higher levels of PPM1G were observed in adverse staged HCCs. The higher levels of PPM1G were highly correlated with poor prognosis, which was further validated in the TCGA cohort. The knockdown of PPM1G inhibited the cell growth and invasion of HCC cell lines. Further studies showed that the knockdown of PPM1G inhibited tumor growth in vivo. The mechanistic analysis showed that the PPM1G interacted with proteins related to alternative splicing, including SRSF3. Overexpression of PPM1G promoted the dephosphorylation of SRSF3 and changed the alternative splicing patterns of genes related to the cell cycle, the transcriptional regulation in HCC cells. In addition, we also demonstrated that the promoter of PPM1G was activated by multiple transcription factors and co-activators, including MYC/MAX and EP300, MED1, and ELF1. Our study highlighted the essential role of PPM1G in HCC and shed new light on unveiling the regulation of alternative splicing in malignant transformation.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yotaro Ochi ◽  
Kenichi Yoshida ◽  
Ying-Jung Huang ◽  
Ming-Chung Kuo ◽  
Yasuhito Nannya ◽  
...  

AbstractBlast crisis (BC) predicts dismal outcomes in patients with chronic myeloid leukaemia (CML). Although additional genetic alterations play a central role in BC, the landscape and prognostic impact of these alterations remain elusive. Here, we comprehensively investigate genetic abnormalities in 136 BC and 148 chronic phase (CP) samples obtained from 216 CML patients using exome and targeted sequencing. One or more genetic abnormalities are found in 126 (92.6%) out of the 136 BC patients, including the RUNX1-ETS2 fusion and NBEAL2 mutations. The number of genetic alterations increase during the transition from CP to BC, which is markedly suppressed by tyrosine kinase inhibitors (TKIs). The lineage of the BC and prior use of TKIs correlate with distinct molecular profiles. Notably, genetic alterations, rather than clinical variables, contribute to a better prediction of BC prognosis. In conclusion, genetic abnormalities can help predict clinical outcomes and can guide clinical decisions in CML.


Author(s):  
Gargi Kapatia ◽  
Arun Sasikumar Nair Remani ◽  
Shano Naseem ◽  
Mayur Parihar ◽  
Sreejesh Sreedharanunni

2018 ◽  
Vol 79 (8) ◽  
pp. 470-471
Author(s):  
Mesut Sivri ◽  
Yahya Paksoy ◽  
Mehmet Dağlı ◽  
Kazım Serhan Keles˛oğlu ◽  
Mustafa Koplay

2018 ◽  
pp. bcr-2017-223923 ◽  
Author(s):  
Banshi Lal Kumawat ◽  
Chandra Mohan Sharma ◽  
Pankaj Kumar Saini ◽  
Ankur Garg

Oncogene ◽  
2005 ◽  
Vol 24 (20) ◽  
pp. 3257-3267 ◽  
Author(s):  
Kay Barnes ◽  
Elizabeth McIntosh ◽  
Anthony D Whetton ◽  
George Q Daley ◽  
Johanne Bentley ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document